Clinical Trial Update: Iontophoretic Delivery of EGP-437 in Patients Who Have Undergone Cataract Surgery [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating iontophoretic delivery of EGP-437 in patients following cataract surgery has completed, focusing on postoperative inflammation and pain…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cataract

Drugs mentioned

• EGP-437 (dexamethasone phosphate (ocular iontophoresis formulation))

Snippet

Sponsor: Eyegate Pharmaceuticals, Inc. | Conditions: Cataract, Anterior Chamber Inflammation | Phase 2 | Status: COMPLETED